State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan 430079, China.
State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan 430079, China; Department of Oral & Maxillofacial, Anyang Sixth People's Hospital, Anyang 45500, China.
Life Sci. 2024 Jun 1;346:122635. doi: 10.1016/j.lfs.2024.122635. Epub 2024 Apr 13.
The signal transducer and activator of transcription 3 (STAT3), a member of the STAT family, resides in the nucleus to regulate genes essential for vital cellular functions, including survival, proliferation, self-renewal, angiogenesis, and immune response. However, continuous STAT3 activation in tumor cells promotes their initiation, progression, and metastasis, rendering STAT3 pathway inhibitors a promising avenue for cancer therapy. Nonetheless, these inhibitors frequently encounter challenges such as cytotoxicity and suboptimal biocompatibility in clinical trials. A viable strategy to mitigate these issues involves delivering STAT3 inhibitors via drug delivery systems (DDSs). This review delineates the regulatory mechanisms of the STAT3 signaling pathway and its association with cancer. It offers a comprehensive overview of the current application of DDSs for anti-STAT3 inhibitors and investigates the role of DDSs in cancer treatment. The conclusion posits that DDSs for anti-STAT3 inhibitors exhibit enhanced efficacy and reduced adverse effects in tumor therapy compared to anti-STAT3 inhibitors alone. This paper aims to provide an outline of the ongoing research and future prospects of DDSs for STAT3 inhibitors. Additionally, it presents our insights on the merits and future outlook of DDSs in cancer treatment.
信号转导和转录激活因子 3（STAT3）是 STAT 家族的成员，位于细胞核内，调节对细胞生命功能至关重要的基因，包括生存、增殖、自我更新、血管生成和免疫反应。然而，肿瘤细胞中持续的 STAT3 激活促进了它们的起始、进展和转移，使得 STAT3 通路抑制剂成为癌症治疗的一个有前途的途径。尽管如此，这些抑制剂在临床试验中经常遇到细胞毒性和生物相容性不佳等挑战。一种可行的策略是通过药物递送系统（DDS）来递送 STAT3 抑制剂。这篇综述阐述了 STAT3 信号通路的调节机制及其与癌症的关系。它全面概述了 DDS 目前在抗 STAT3 抑制剂中的应用，并研究了 DDS 在癌症治疗中的作用。结论认为，与单独使用抗 STAT3 抑制剂相比，DDS 用于抗 STAT3 抑制剂在肿瘤治疗中具有增强的疗效和降低的不良反应。本文旨在概述 STAT3 抑制剂的 DDS 的研究现状和未来前景。此外，还介绍了我们对 DDS 在癌症治疗中的优点和未来前景的看法。
